Follow-Up of PRRSv-Vaccinated Piglets Born from PRRSv-Vaccinated, ELISA-Seropositive and ELISA-Seronegative Sows

Vaccination against the porcine reproductive and respiratory syndrome virus (PRRSv) is widely used to prevent production losses in the swine industry. In this study, piglets born from both PRRSv-vaccinated ELISA-seropositive sows (E+ piglets) and PRRSv-vaccinated ELISA-seronegative sows (E− piglets) were followed-up pre-vaccination, 3 weeks post-vaccination (wpv) and 8 wpv in two Belgian farrow-to-finish herds. The aim of the study was to analyze the presence of PRRSv-specific maternally-derived antibodies (MDAs) and the PRRSv vaccine response in both groups of piglets. The E− piglets lacked the presence of PRRSv-specific MDAs (0% seropositive), while these were present in the E+ piglets (97% seropositive). Due to this, the E− piglets showed a strong initial vaccine response (72–80% seroconversion) and vaccine viremia (65–75% PCR positive) at 3 wpv. In contrast, the E+ piglets showed only limited initial vaccine responses (25–61% with increased ELISA values) and vaccine viremia (30–31% PCR positive) at 3 wpv. By 8 wpv, the proportion of seropositive E− piglets (78–100%) and seropositive E+ piglets (55–90%) increased in both herds. However, a difference in vaccine viremia duration was observed between both herds at 8 wpv, with a decrease in the proportion of PCR positive piglets in herd 1 (E−: 47%; E+: 25%) and an increase in the proportion of PCR positive piglets in herd 2 (E−: 85%; E+: 92%). This study identified clear differences in the presence of PRRSv-specific maternally-derived antibodies and PRRSv vaccine responses between E− and E+ piglets. Further research is warranted to elicit the biological relevance of these observed differences